ArticleThe Journal of hand surgery2025
SARM1 Inhibition Maintains Axonal Integrity After Rat Sciatic Nerve Transection and Repair.
Article in The Journal of hand surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Wallerian Degeneration and Nerve Regeneration-A Review of Cellular and Molecular Events.International journal of molecular sciences · 2026Review
- Advancing Peripheral Nerve Regeneration (Nerve SPACE 2025).Journal of hand surgery global online · 2026Article
- Mechanisms, translational opportunities for diabetic polyneuropathy.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeSterile alpha and TlR motif containing-1 (SARM1) protein has been demonstrated to play a critical role in the initiation of Wallerian degeneration after nerve injury. The goal of this study was to assess whether blockade of SARM1 activity inhibits Wallerian degeneration following nerve transection, potentially promoting more rapid recovery of axonal function.
methodsAn adeno-associated virus plasmid encoded with a dominant-negative SARM1 protein fused with green fluorescent protein to impair SARM1 function, was injected into 24 juvenile rats to create a SARM1 dominant-negative (SARM1-DN) phenotype. Twenty-four control rats were injected with a control plasmid expressing only green fluorescent protein. Three weeks after transfection, the rats underwent unilateral sciatic nerve transection and repair. Walking track analysis and nonsurvival surgeries were performed at 2 days, 2 weeks, or 6 weeks to assess muscle strength and compound nerve action potential. Histomorphologic and electrodiagnostic studies were evaluated with mixed-effect analysis.
resultsHistomorphologic analysis showed maintenance of axons in the SARM1-DN animals at 2 weeks, with significantly improved compound nerve action potential amplitude. Muscle testing demonstrated greater gastrocnemius strength in SARM1 DN muscles at 2 days and 2 weeks compared to controls, although this was not maintained at 6 weeks.
conclusionInhibition of SARM1 resulted in early increases in number and myelination of axons and action potential after sciatic nerve transection and repair in SARM1-DN rats. CLINICAL RELEVANCE: SARM1 inhibition may offer the potential to delay Wallerian degeneration following nerve transection and enable earlier functional recovery of motor strength. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.